TY  -  
T1  - Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs 
SN  -  /  
UR  - http://hdl.handle.net/10138/332459 
T3  -  
A1  - Herring, Shawn; Oda, Jessica M.; Wagoner, Jessica; Kirchmeier, Delaney; O'Connor, Aidan; Nelson, Elizabeth A.; Huang, Qinfeng; Liang, Yuying; DeWald, Lisa Evans; Johansen, Lisa M.; Glass, Pamela J.; Olinger, Gene G.; Ianevski, Aleksandr; Aittokallio, Tero; Paine, Mary F.; Fink, Susan L.; White, Judith M.; Polyak, Stephen J. 
A2  -  
PB  -  
Y1  - 2021 
LA  - eng 
AB  - Neglected diseases caused by arenaviruses such as Lassa virus (LASV) and filoviruses like Ebola virus (EBOV) primarily afflict resource-limited countries, where antiviral drug development is often minimal. Previous studies have shown that many approved drugs developed for other clinical indications inhibit EBOV and LASV and that combinations of these drugs provide synergistic suppression of EBOV, often by blocking discrete steps in virus entry. We hypothesize that repurposing of combinations of ... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - arenavirus; filovirus; Lassa; Junin; Pichinde; Ebola; Marburg; arbidol; repurposing; broad-spectrum antiviral; SARS-CoV-2; synergy; SynergyFinder2; EBOLA-VIRUS; ANTIVIRAL ACTIVITY; ARBIDOL; PHARMACOKINETICS; FUSION; IDENTIFICATION; ARIPIPRAZOLE; INFLUENZA; MECHANISM; SINGLE; 11832 Microbiology and virology; 317 Pharmacy 
N1  -   
PP  -  
ER  -